- Abstract covering Phase 2 osteoarthritis trial results accepted
as a late-breaking submission
VICTORIA, BC, Nov. 1, 2023
/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company")
(TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an
innovative drug delivery technology, today announced late-breaking
acceptance of the Company's abstract for a poster presentation
at the 2023 Annual Meeting of the American College of
Rheumatology.
The meeting is being held at the San
Diego Convention Center from November
10-15, 2023, in San Diego,
CA. Late-breaking acceptance is typically reserved for
important clinical trial results and groundbreaking science.
Eupraxia's Chief Scientific Officer, Amanda
Malone, will present the poster highlighting the Company's
Phase 2b data for EP-104IAR. Key
highlights from the study include:
- Meeting the primary endpoint and three key secondary
endpoints;
- Data supporting clinically meaningful and durable pain relief;
and
- Pharmacokinetic and safety data that support the potential for
chronic and bilateral dosing.
"We were pleased to be accepted as a late-breaking
abstract based on the clinically meaningful data from our Phase
2b trial in knee osteoarthritis as we
work to highlight the findings with clinicians, key opinion leaders
and the broader pharmaceutical industry," said Dr. James Helliwell, CEO of Eupraxia. "As we focus
on highlighting our strong Phase 2b
results, we are also continuing to work toward advancing EP-104IAR
into late-stage clinical testing to further demonstrate the
potential of this product candidate in patients with osteoarthritis
of the knee."
Poster Title: EP-104IAR (Extended-Release Fluticasone
Propionate for Injectable Suspension): Topline and Key Secondary
Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled
Trial in Subjects with Knee Osteoarthritis.
Session Title: Late-Breaking Posters (L01 - L14)
Date: Tuesday, November 14,
2023
Presentation Time: 9:00 AM - 11:00
AM
Abstract ID: 1644341
Poster Number: L04
The poster presentation will also be available on Eupraxia's
website at:
https://eupraxiapharma.com/our-science/clinical-trials-and-publications/default.aspx
About Eupraxia Pharmaceuticals
Inc.
Eupraxia is a clinical-stage biotechnology company focused on
the development of locally delivered, extended-release products
that have the potential to address therapeutic areas with high
unmet medical need. The Company strives to provide improved patient
benefit and has developed technology that delivers targeted,
long-lasting activity with fewer side effects.
Eupraxia's lead product candidate, EP-104IAR, recently completed
a Phase 2b clinical trial for the
treatment of pain due to osteoarthritis of the knee. EP-104IAR met
its primary endpoint and three of the four secondary endpoints. The
EP-104 platform has expanded into gastrointestinal disease and has
initiated a Phase 1b/2a program to
treat eosinophilic esophagitis. Eupraxia is also developing a
pipeline of later- and earlier-stage long-acting formulations.
Potential pipeline indications include candidates for both other
inflammatory joint indications and oncology, each designed to
improve on the activity and tolerability of currently approved
drugs. For further details about Eupraxia, please visit the
Company's website at: www.eupraxiapharma.com.
Forward-Looking
Statements
This news release includes forward-looking statements and
forward-looking information within the meaning of Canadian
securities laws. Often, but not always, forward-looking information
can be identified by the use of words such as "plans", "is
expected", "expects", "scheduled", "intends", "contemplates",
"anticipates", "believes", "proposes" or variations (including
negative and grammatical variations) of such words and phrases, or
state that certain actions, events or results "may", "could",
"would", "might" or "will" be taken, occur or be achieved.
Forward-looking statements in this news release include statements
regarding the Company's business strategies and objectives,
including current and future plans and opportunities, expectations
and intentions; statements regarding the Company's ongoing clinical
trials and pipeline development; the ability of the Company to
execute on its business strategy; the Company's planned poster
presentation at the 2023 Annual Meeting of the American College of
Rheumatology; the potential of Eupraxia's product candidates,
including the advancement of EP-104IAR for treating knee
osteoarthritis; the Company's expectations regarding its product
designs, including with respect to potential benefits, targeted
shelf life, storage, ease of integration, duration, tolerability,
effectiveness and safety; the results gathered from studies of
Eupraxia's product candidates, including certain data to support
the potential for chronic and bilateral dosing; the potential for
the Company's technology to impact the drug delivery process; the
competitive advantages of the Company's technology; the benefits to
patients from the Company's drug platforms; and the translation of
the Company's technologies and expansion of its offerings into
clinical applications.
Such statements and information are based on the current
expectations of Eupraxia's management, and are based on
assumptions, including but not limited to: future research and
development plans for the Company proceeding substantially as
currently envisioned; industry growth trends, including with
respect to projected and actual industry sales; the Company's
ability to obtain positive results from the Company's research and
development activities, including clinical trials; and the
Company's ability to protect patents and proprietary rights.
Although Eupraxia's management believes that the assumptions
underlying these statements and information are reasonable, they
may prove to be incorrect. The forward-looking events and
circumstances discussed in this news release may not occur by
certain dates or at all and could differ materially as a result of
known and unknown risk factors and uncertainties affecting
Eupraxia, including, but not limited to: the Company's limited
operating history; the Company's novel technology with uncertain
market acceptance; if the Company breaches any of the agreements
under which it licenses rights to its product candidates or
technology from third parties, the Company could lose license
rights that are important to its business; the Company's current
license agreement may not provide an adequate remedy for its breach
by the licensor; the Company's technology may not be successful for
its intended use; the Company's future technology will require
regulatory approval, which is costly and the Company may not be
able to obtain it; the Company may fail to obtain regulatory
approvals or only obtain approvals for limited uses or indications;
the Company's clinical trials may fail to demonstrate adequately
the safety and efficacy of its product candidates at any stage of
clinical development; the Company may be required to suspend or
discontinue clinical trials due to side effects or other safety
risks; the Company completely relies on third parties to provide
supplies and inputs required for its products and services; the
Company relies on external contract research organizations to
provide clinical and non-clinical research services; the Company
may not be able to successfully execute its business strategy; the
Company will require additional financing, which may not be
available; any therapeutics the Company develops will be subject to
extensive, lengthy and uncertain regulatory requirements, which
could adversely affect the Company's ability to obtain regulatory
approval in a timely manner, or at all; the impact of the COVID-19
pandemic on the Company's operations; and other risks and
uncertainties described in more detail in Eupraxia's public filings
on SEDAR+ (www.sedarplus.ca). Although Eupraxia has attempted to
identify important factors that could cause actual actions, events
or results to differ materially from those described in
forward-looking statements and information, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement or
information can be guaranteed. Except as required by applicable
securities laws, forward-looking statements and information speak
only as of the date on which they are made and Eupraxia undertakes
no obligation to publicly update or revise any forward-looking
statement or information, whether as a result of new information,
future events or otherwise.
SOURCE Eupraxia Pharmaceuticals Inc.